Status:

COMPLETED

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Primary Hyperoxaluria Type 1 (PH1)

Primary Hyperoxaluria Type 2 (PH2)

Eligibility:

All Genders

6+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)

Eligibility Criteria

Inclusion

  • Key
  • Capable and willing to provide written informed consent or assent
  • Documented diagnosis of PH1 or PH2, confirmed by genotyping
  • Must meet the 24 hour urine oxalate excretion requirements
  • Less than 20% variation between the two 24-hour urinary creatinine excretion values derived from the two 24-hour urine collections in the screening period
  • Estimated GFR at screening ≥ 30 mL/min normalized to 1.73 m2 BSA
  • Key

Exclusion

  • Renal or hepatic transplantation (prior or planned within the study period)
  • Currently on dialysis or anticipated requirement for dialysis during the study period
  • Plasma oxalate \>30 µmol/L
  • Documented evidence of clinical manifestations of systemic oxalosis (including pre-existing retinal, heart, or skin calcifications, or history of severe bone pain, pathological fractures, or bone deformations)
  • Use of an RNA interference (RNAi) drug within the last 6 months
  • Participation in any clinical study in which you received an investigational medicinal product (IMP) within 4 months before Screening
  • Liver function test (LFT) abnormalities: Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>1.5 times upper limit of normal (ULN) for age and gender
  • Inability or unwillingness to comply with study procedures

Key Trial Info

Start Date :

October 28 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 29 2021

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT03847909

Start Date

October 28 2019

End Date

June 29 2021

Last Update

May 22 2024

Active Locations (28)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (28 locations)

1

Clinical Trial Site

San Francisco, California, United States, 94143

2

Clinical Trial Site

Boston, Massachusetts, United States, 02115

3

Clinical Trial Site

Rochester, Minnesota, United States, 55905

4

Clinical Trial Site

New York, New York, United States, 10016